Rescuing the guardian of the genome

  1. Robert F. Service

Science  07 Oct 2016:
Vol. 354, Issue 6308, pp. 26-28
DOI: 10.1126/science.354.6308.26

Robert F. Service

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF


You are currently viewing the summary.

View Full Text


This article is available to AAAS members. If you are a AAAS Member use your via AAAS ID and password to log in. Not a member? Click here to join.

Via your Institution

Log in through your institution

If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.

Log in through your institution

You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.

  • Purchase Article
  • Activate Member Account
  • Renew Subscription
  • Recommend a subscription to your library
  • Help for librarians

Free with registration

Science research is available free with registration one year after initial publication. To get your free access please visit our registration form.


P53 is a protein that plays a critical role in preventing cells with DNA damage or other cellular insults from turning cancerous. The protein is mutated in about half of all human cancers. When that happens p53 is unable to fold up into its normal 3D shape, which prevents it from latching onto DNA and sounding the cellular alarm in response to damage. Researchers have long tried to combat cancer by boosting the number of copies of healthy p53 in cells, and a number of drugs that do that remain in human trials. But none has yet made it to market. Now, researchers are making headway on a new approach, finding drugs that prop up mutated p53 and restore its proper shape so that it can once again bind DNA and signal for help. One such drug has already passed an initial human trial and others are on the way. If any succeed, they could change the landscape of cancer therapy and perhaps pave the way for other protein-rescuing drugs to combat protein-misfolding diseases such as Alzheimer’s and Parkinson’s.

Science: 354 (6308)


  • Table of Contents
  • Print Table of Contents
  • Advertising (PDF)
  • Classified (PDF)
  • Masthead (PDF)

Article Tools

  • Email

    Thank you for your interest in spreading the word about Science.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.

    Rescuing the guardian of the genome

    (Your Name) has forwarded a page to you from Science

    (Your Name) thought you would like to see this page from the Science web site.

  • Download Powerpoint

  • Print

  • Save to my folders

  • Alerts

    Please log in to add an alert for this article.

    Enter your username.

    Enter the password that accompanies your username.

  • Citation tools

    Rescuing the guardian of the genome

    New drugs combat cancer by propping up a mutated tumor-fighting protein.

    Citation Manager Formats

  • Share

    Rescuing the guardian of the genome

    New drugs combat cancer by propping up a mutated tumor-fighting protein.


    CiteULike logo Connotea logo logo Digg logo Facebook logo Google logo Mendeley logo Reddit logo Twitter logo

Related Content

Similar Articles in:

Citing Articles in:

Related Jobs from ScienceCareers

  • Cell Biology
  • Genetics
  • Medicine, Diseases
  • Molecular Biology
  • Pharmacology, Toxicology


11 November 2016

Vol 354, Issue 6313

Magazine Cover

  • Feature

    The lost norse

  • Technology Governance

    Precaution and governance of emerging technologies

  • Genetic Engineering

    Tinkering with evolution


    News at a glance

  • Epidemiology

    Leprosy in red squirrels

  • Working Life

    The problem with ‘alternative’

Table of Contents

Post Author: Tech Review